keyword
MENU ▼
Read by QxMD icon Read
search

Cannabinoids and epilepsy

keyword
https://www.readbyqxmd.com/read/28276775/cannabinoids-therapeutic-use-what-is-our-current-understanding-following-the-introduction-of-thc-thc-cbd-oromucosal-spray-and-others
#1
Mauro Maccarrone, Rafael Maldonado, Miguel Casas, Thomas Henze, Diego Centonze
The complexity of the endocannabinoid (eCB) system is becoming better understood and new drivers of eCB signaling are emerging. Modulation of the activities of the eCB system can be therapeutic in a number of diseases. Research into the eCB system has been paralleled by the development of agents that interact with cannabinoid receptors. In this regard it should be remembered that herbal cannabis contains a myriad of active ingredients, and the individual cannabinoids have quite distinct biological activities requiring independent studies...
February 28, 2017: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/28254350/the-current-status-of-artisanal-cannabis-for-the-treatment-of-epilepsy-in-the-united-states
#2
Dustin Sulak, Russell Saneto, Bonni Goldstein
The widespread patient use of artisanal cannabis preparations has preceded quality validation of cannabis use for epilepsy. Neurologists and cannabinoid specialists are increasingly in a position to monitor and guide the use of herbal cannabis in epilepsy patients. We report the retrospective data on efficacy and adverse effects of artisanal cannabis in Patients with medically refractory epilepsy with mixed etiologies in Washington State, California, and Maine. Clinical considerations, including potential risks and benefits, challenges related to artisanal preparations, and cannabinoid dosing, are discussed...
February 18, 2017: Epilepsy & Behavior: E&B
https://www.readbyqxmd.com/read/28238865/an-australian-nationwide-survey-on-medicinal-cannabis-use-for-epilepsy-history-of-antiepileptic-drug-treatment-predicts-medicinal-cannabis-use
#3
Anastasia S Suraev, Lisa Todd, Michael T Bowen, David J Allsop, Iain S McGregor, Carol Ireland, Nicholas Lintzeris
Epilepsy Action Australia conducted an Australian nationwide online survey seeking opinions on and experiences with the use of cannabis-based products for the treatment of epilepsy. The survey was promoted via the Epilepsy Action Australia's main website, on their Facebook page, and by word of mouth. The survey consisted of 39 questions assessing demographics, clinical factors, including diagnosis and seizure types, and experiences with and opinions towards cannabis use in epilepsy. A total of 976 responses met the inclusion criteria...
February 24, 2017: Epilepsy & Behavior: E&B
https://www.readbyqxmd.com/read/28237318/strokes-are-possible-complications-of-cannabinoids-use
#4
REVIEW
Valérie Wolff, Emilie Jouanjus
It is critically important to identify all factors that may play a role in the recent increase of the incidence of stroke among the young population. Considering the worldwide use of cannabinoids (cannabis and synthetic cannabinoids), the recent legalization of their consumption in some countries, and their supposed involvement in cardiovascular events, we evaluated their role in the occurrence of neurovascular complications among the young. Ninety-eight patients were described in the literature as having a cannabinoids-related stroke (85 after cannabis use and 13 after synthetic cannabinoids)...
February 23, 2017: Epilepsy & Behavior: E&B
https://www.readbyqxmd.com/read/28236578/social-correlates-of-health-status-quality-of-life-and-mood-states-in-patients-treated-with-cannabidiol-for-epilepsy
#5
Magdalena Szaflarski, Barbara Hansen, E Martina Bebin, Jerzy P Szaflarski
Social characteristics, such as socioeconomic status and race/ethnicity, play a role in the treatment and outcomes of patients with epilepsy (PWE), but little is known about how these factors affect patients receiving cannabidiol (CBD) to treat seizures. This exploratory study examined the sociodemographic profile of patients treated with CBD (n=80) and associations between social factors and patient-centered outcomes - overall health status, Quality of Life in Epilepsy-89 (QOLIE-89), and Profile of Mood States (POMS) - in this population...
February 21, 2017: Epilepsy & Behavior: E&B
https://www.readbyqxmd.com/read/28215997/cannabinoids-and-epilepsy-introduction
#6
EDITORIAL
Jerzy P Szaflarski, Orrin Devinsky
No abstract text is available yet for this article.
February 16, 2017: Epilepsy & Behavior: E&B
https://www.readbyqxmd.com/read/28202406/cannabis-cultivation-methodological-issues-for-obtaining-medical-grade-product
#7
REVIEW
Suman Chandra, Hemant Lata, Mahmoud A ElSohly, Larry A Walker, David Potter
As studies continue to reveal favorable findings for the use of cannabidiol in the management of childhood epilepsy syndromes and other disorders, best practices for the large-scale production of Cannabis are needed for timely product development and research purposes. The processes of two institutions with extensive experience in producing large-scale cannabidiol chemotype Cannabis crops-GW Pharmaceuticals and the University of Mississippi-are described, including breeding, indoor and outdoor growing, harvesting, and extraction methods...
February 12, 2017: Epilepsy & Behavior: E&B
https://www.readbyqxmd.com/read/28190698/therapeutic-effects-of-cannabinoids-in-animal-models-of-seizures-epilepsy-epileptogenesis-and-epilepsy-related-neuroprotection
#8
REVIEW
Evan C Rosenberg, Pabitra H Patra, Benjamin J Whalley
The isolation and identification of the discrete plant cannabinoids in marijuana revived interest in analyzing historical therapeutic claims made for cannabis in clinical case studies and anecdotes. In particular, sources as old as the 11th and 15th centuries claimed efficacy for crude marijuana extracts in the treatment of convulsive disorders, prompting a particularly active area of preclinical research into the therapeutic potential of plant cannabinoids in epilepsy. Since that time, a large body of literature has accumulated describing the effects of several of the >100 individual plant cannabinoids in preclinical models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection...
February 9, 2017: Epilepsy & Behavior: E&B
https://www.readbyqxmd.com/read/28188044/cannabinoids-in-treatment-resistant-epilepsy-a-review
#9
REVIEW
Brooke K O'Connell, David Gloss, Orrin Devinsk
Treatment-resistant epilepsy (TRE) affects 30% of epilepsy patients and is associated with severe morbidity and increased mortality. Cannabis-based therapies have been used to treat epilepsy for millennia, but only in the last few years have we begun to collect data from adequately powered placebo-controlled, randomized trials (RCTs) with cannabidiol (CBD), a cannabis derivative. Previously, information was limited to case reports, small series, and surveys reporting on the use of CBD and diverse medical marijuana (MMJ) preparations containing: tetrahydrocannabinol (THC), CBD, and many other cannabinoids in differing combinations...
February 7, 2017: Epilepsy & Behavior: E&B
https://www.readbyqxmd.com/read/28169144/the-legal-status-of-cannabis-marijuana-and-cannabidiol-cbd-under-u-s-law
#10
REVIEW
Alice Mead
In the United States, federal and state laws regarding the medical use of cannabis and cannabinoids are in conflict and have led to confusion among patients, caregivers, and healthcare providers. Currently, cannabis is legal for medical purposes in 50% of the states, and another seventeen states allow products that are high in cannabidiol (CBD) and low in THC (tetrahydrocannabinol) for medical use. Many of these artisanal products are sold in dispensaries or over the internet. However, none of these products has been approved by the Food and Drug Administration (FDA)...
February 3, 2017: Epilepsy & Behavior: E&B
https://www.readbyqxmd.com/read/28132734/social-factors-in-marijuana-use-for-medical-and-recreational-purposes
#11
REVIEW
Magdalena Szaflarski, Joseph I Sirven
Of all the various treatment options for epilepsy, no other therapy comes close to the polarity that cannabis engenders. The rationale for this reaction is firmly rooted in the social factors that enshroud the use of marijuana for both medical and recreational purposes. In order to best understand how to approach this controversial treatment, it is essential to explore the social, demographic, and historical variables that have led to the current opinions on cannabis therapy and how this has converged on epilepsy treatment...
January 26, 2017: Epilepsy & Behavior: E&B
https://www.readbyqxmd.com/read/28112710/are-cannabinoids-effective-for-epilepsy
#12
Javier Peña, Gabriel Rada
Several beneficial effects have been proposed for cannabinoids in different clinical conditions, including epilepsy. However, their clinical role is controversial. Searching in Epistemonikos database, which is maintained by screening multiple databases, we identified five systematic reviews including four randomized trials addressing the question of this article. We extracted data and generated a summary of findings following the GRADE approach. We concluded it is not clear whether cannabinoids reduce the frequency of seizures in epilepsy because the certainty of the evidence is very low, and they probably increase adverse effects...
January 13, 2017: Medwave
https://www.readbyqxmd.com/read/28109780/neuroimaging-studies-towards-understanding-the-central-effects-of-pharmacological-cannabis-products-on-patients-with-epilepsy
#13
REVIEW
Jane B Allendorfer, Jerzy P Szaflarski
Recent interest for the use of cannabis-derived products as therapeutic agents in the treatment of epilepsies has necessitated a reevaluation of their effects on brain and behavior. Overall, prolonged cannabis use is thought to result in functional and structural brain alterations. These effects may be dependent on a number of factors: e.g., which phytocannabinoid is used (e.g., cannabidiol (CBD) vs. tetrahyrocannabinol (THC)), the frequency of use (occasional vs. heavy), and at what age (prenatal, childhood, adulthood) the use began...
January 18, 2017: Epilepsy & Behavior: E&B
https://www.readbyqxmd.com/read/28089286/historical-perspective-on-the-medical-use-of-cannabis-for-epilepsy-ancient-times-to-the-1980s
#14
REVIEW
Daniel Friedman, Joseph I Sirven
There has been a dramatic surge in the interest of utilizing cannabis for epilepsy treatment in the US. Yet, access to cannabis for research and therapy is mired in conflicting regulatory policies and shifting public opinion. Understanding the current state of affairs in the medical cannabis debate requires an examination of the history of medical cannabis use. From ancient Chinese pharmacopeias to the current Phase III trials of pharmaceutical grade cannabidiol, this review covers the time span of cannabis use for epilepsy therapy so as to better assess the issues surrounding the modern medical opinion of cannabis use...
January 11, 2017: Epilepsy & Behavior: E&B
https://www.readbyqxmd.com/read/28087250/pharmacology-of-cannabinoids-in-the-treatment-of-epilepsy
#15
REVIEW
Tyler E Gaston, Daniel Friedman
The use of cannabis products in the treatment of epilepsy has long been of interest to researchers and clinicians alike; however, until recently very little published data were available to support its use. This article summarizes the available scientific data of pharmacology from human and animal studies on the major cannabinoids which have been of interest in the treatment of epilepsy, including ∆9-tetrahydrocannabinol (∆9-THC), cannabidiol (CBD), ∆9-tetrahydrocannabivarin (∆9-THCV), cannabidivarin (CBDV), and ∆9-tetrahydrocannabinolic acid (Δ9-THCA)...
January 10, 2017: Epilepsy & Behavior: E&B
https://www.readbyqxmd.com/read/27989385/cannabis-and-epilepsy-an-ancient-treatment-returns-to-the-fore
#16
REVIEW
Ethan B Russo
Cannabis has been associated with the treatment of epilepsy throughout history, and if ancient Assyrian sources referring to "hand of ghost" are considered credible, this relationship may span four millennia. A tradition of usage continued in Arabic medicine and Ayurvedic practice in India, which led, in turn, to early experiments in Europe and North America with "Indian hemp." Lack of standardization, bioavailability issues, and ultimately prohibition were all factors in cannabis-based medicines failing to maintain mainstream usage in seizure treatment, but investigation was resumed in the 1970s with interesting signals noted in both laboratory and clinical settings...
December 15, 2016: Epilepsy & Behavior: E&B
https://www.readbyqxmd.com/read/27851727/high-resolution-crystal-structure-of-the-human-cb1-cannabinoid-receptor
#17
Zhenhua Shao, Jie Yin, Karen Chapman, Magdalena Grzemska, Lindsay Clark, Junmei Wang, Daniel M Rosenbaum
The human cannabinoid G-protein-coupled receptors (GPCRs) CB1 and CB2 mediate the functional responses to the endocannabinoids anandamide and 2-arachidonyl glycerol (2-AG), as well as the widely consumed plant (phyto)cannabinoid Δ(9)-tetrahydrocannabinol (THC)(1). The cannabinoid receptors have been the targets of intensive drug discovery efforts owing to the therapeutic potential of modulators for controlling pain(2), epilepsy(3), obesity(4), and other maladies. Although much progress has recently been made in understanding the biophysical properties of GPCRs, investigations of the molecular mechanisms of the cannabinoids and their receptors have lacked high-resolution structural data...
November 16, 2016: Nature
https://www.readbyqxmd.com/read/27810514/endogenous-cannabinoid-system-alterations-and-their-role-in-epileptogenesis-after-brain-injury-in-rat
#18
Xiu Wang, Yao Wang, Chao Zhang, Chang Liu, Hai-Feng Yang, Wen-Han Hu, Jian-Guo Zhang, Kai Zhang
Post-traumatic epilepsy (PTE) is one of the most common complications resulting from brain injury, however, antiepileptic drugs usually fail to prevent it. Several lines of evidence have demonstrated that the endogenous cannabinoid system (ECS) plays a pivotal role during epileptogenesis in several animal models. A recent study has shown that a cannabinoid type 1 (CB1) receptor antagonist could suppress long-term neuron hyperexcitability after brain injury, but the underlying mechanisms remain largely unknown...
December 2016: Epilepsy Research
https://www.readbyqxmd.com/read/27790143/a-personal-retrospective-elevating-anandamide-aea-by-targeting-fatty-acid-amide-hydrolase-faah-and-the-fatty-acid-binding-proteins-fabps
#19
Dale G Deutsch
This perspective was adapted from a Career Achievement Award talk given at the International Cannabinoid Research Society Symposium in Bukovina, Poland on June 27, 2016. As a biochemist working in the neurosciences, I was always fascinated with neurotransmitter inactivation. In 1993 we identified an enzyme activity that breaks down anandamide. We called the enzyme anandamide amidase, now called FAAH. We and other laboratories developed FAAH inhibitors that were useful reagents that also proved to have beneficial physiological effects and until recently, new generations of inhibitors were in clinical trials...
2016: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/27790138/splendor-in-the-grass-a-pilot-study-assessing-the-impact-of-medical-marijuana-on-executive-function
#20
Staci A Gruber, Kelly A Sagar, Mary K Dahlgren, Megan T Racine, Rosemary T Smith, Scott E Lukas
Currently, 25 states and Washington DC have enacted full medical marijuana (MMJ) programs while 18 states allow limited access to MMJ products. Limited access states permit low (or zero) tetrahydrocannabinol (THC) and high cannabidiol (CBD) products to treat specified conditions such as uncontrolled epilepsy. Although MMJ products are derived from the same plant species as recreational MJ, they are often selected for their unique cannabinoid constituents and ratios, not typically sought by recreational users, which may impact neurocognitive outcomes...
2016: Frontiers in Pharmacology
keyword
keyword
78747
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"